Following the June decision by a CDC committee to recommend against any use of AstraZeneca’s FluMist Quadrivalent for the upcoming flu season, a Canadian study…

Dynavax Technologies has a new FDA Adcomm date for consideration of its hepatitis B vaccine, Heplisav-B, after the agency earlier this year pushed back its…

Scientists have been developing vaccines that could stop disease outbreaks more quickly. Now, researchers at the Massachusetts Institute of Technology are…

Vaxart has been keeping busy with R&D for its oral vaccines, and now, the company is adding another project to its list. The South San Francisco-based…

Pfizer’s Prevnar 13 sales were down in Q2 after management laid out low projections for the vaccine in 2016. But things could pick up again for Prevnar thanks…

Nearly a year after raising $12 million to advance its universal flu vaccine candidate into human trials, Madison, WI’s FluGen is heading to the clinic. The…

Gaithersburg, MD’s Altimmune has secured a sizable government contract to further develop its nasal spray anthrax vaccine candidate, building on an existing…

On the heels of devastating Phase III trial results for its pancreatic cancer vaccine, NewLink Genetics will undergo a restructuring, downsizing by 100…